Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

14.00
-0.4400-3.05%
Post-market: 13.95-0.0500-0.36%19:49 EDT
Volume:3.04M
Turnover:42.62M
Market Cap:1.10B
PE:6.90
High:14.52
Open:14.30
Low:13.95
Close:14.44
52wk High:16.91
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:2.23
T/O Rate:4.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:4.75
PE(LYR):7.49

Loading ...

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

GlobeNewswire
·
Jun 14

SIMCERE PHARMA Receives NMPA Approval for Clinical Trial of SIM0689, a Dual-Target Antibody

Stock News
·
Jun 12

Simcere Wins NMPA Green Light for PD-1/VEGF Bispecific Cancer Therapy

TIPRANKS
·
Jun 12

PagerDuty survey finds 66% of office professionals use unauthorized AI tools at work

Reuters
·
Jun 11

Press Release: AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

Dow Jones
·
Jun 11

Southwest Securities: Post-PD-(L)1 Treatment Resistance Poses Significant Challenge, 2026 to See High Concentration of Catalysts

Stock News
·
Jun 11

PagerDuty announces Ingram Micro as authorized distributor in Australia

TIPRANKS
·
Jun 09

PagerDuty names Ingram Micro exclusive distributor in Australia

Reuters
·
Jun 09

PagerDuty Expands Australia Footprint With Exclusive Distribution Agreement With Ingram Micro

THOMSON REUTERS
·
Jun 09

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

GlobeNewswire
·
Jun 08

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

GlobeNewswire
·
Jun 06

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

GlobeNewswire
·
Jun 05

PagerDuty price target raised to $10 from $7 at Morgan Stanley

TIPRANKS
·
Jun 03

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

Agilent receives FDA approval for expanded use of PD-L1 IHC 22C3 pharmDx

TIPRANKS
·
Jun 03

PagerDuty management presents at BofA Securities Global Technology Conference

Reuters
·
Jun 01

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

GlobeNewswire
·
Jun 01

Analysts Conflicted on These Technology Names: PagerDuty (PD), Snowflake (SNOW) and Microsoft (MSFT)

TIPRANKS
·
Jun 01

AKESO Shares Surge on Positive Phase III Lung Cancer Trial Data

Stock News
·
Jun 01

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

GlobeNewswire
·
May 31